A Japanese biotechnology company has announced plans to initiate clinical trials for an innovative stem cell-based treatment targeting diabetes patients. The startup’s therapeutic approach represents a significant milestone in regenerative medicine applications within Japan’s growing healthtech sector.
Source: Nikkei Asia Read Full Story